پزشکی شخصی در اختلال هراس: اکنون ما کجا هستیم؟ تجزیه و تحلیل رگرسیون
|کد مقاله||سال انتشار||تعداد صفحات مقاله انگلیسی||ترجمه فارسی|
|116685||2017||13 صفحه PDF||سفارش دهید|
نسخه انگلیسی مقاله همین الان قابل دانلود است.
هزینه ترجمه مقاله بر اساس تعداد کلمات مقاله انگلیسی محاسبه می شود.
این مقاله تقریباً شامل 10113 کلمه می باشد.
هزینه ترجمه مقاله توسط مترجمان با تجربه، طبق جدول زیر محاسبه می شود:
Publisher : Elsevier - Science Direct (الزویر - ساینس دایرکت)
Journal : Personalized Medicine in Psychiatry, Volumes 1â2, MarchâApril 2017, Pages 26-38
Personalized medicine assumes that individualâs unique characteristics are central in tailoring effective pharmacological interventions. The identification of predictors of pharmacotherapy effectiveness is crucial in panic disorder (PD), but consensus on this topic is still lacking. Consequently, we carried out a meta-analysis, according to PRISMA guidelines, with the aim of identifying sociodemographic and clinical moderators of short-term outcomes and tolerability of US FDA-approved medications for PD. We performed a database search on randomized placebo-controlled trials using PubMed, PsycINFO, and Embase. Through the selection process, we finally meta-analyzed 29 comparisons between paroxetine, venlafaxine XR or alprazolam and placebo. We employed the random-effects meta-regression technique. The major results were that longer illness duration was significantly associated with a lower rate of patients free from panic attacks at the end of trials with venlafaxine XR, and that higher age at the beginning of trials was significantly associated with a higher rate of dropouts because of side effects during trials with paroxetine. In addition, longer treatment was associated with a higher rate of patients free from panic attacks at endpoint in trials with venlafaxine XR. Overall, we found limited support for the moderating effects of sociodemographic and clinical variables on the short-term pharmacotherapy for PD. However, our results should be considered with caution considering the limited statistical power and the risk of publication bias. Future studies are needed to overcome the paucity of available data and the shortcoming of the current pharmacological studies in PD.